iPSC-derived neural cells for drug discovery of mitochondrial brain diseases

Speakers
  • Independent Team Leader, Max Delbrueck Center for Molecular Medicine (MDC)
    Biography
      Dr. Prigione is an Independent Team Leader at the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. His group was established in 2015 with the generous support of a junior investigator grant from the German Ministry of Education and Research (BMBF).
      Dr. Prigione received a M.D. from the University of Milan in 2002 and a Ph.D. from the San Raffaele Institute of Milan in 2008. During his Ph.D., Dr. Prigione worked on neurological diseases at the University of Milan-Bicocca and on mitochondrial disorders at the University of California in Davis, USA. As postdoctoral scientist at the Max Planck Institute for Molecular Genetics in Berlin, Dr. Prigione described for the first time the reconfiguration occurring to mitochondria during the reprogramming of human fibroblasts to iPSCs.
      The focus of the Prigione lab is now the application of iPSCs in modeling and treatment discovery of neurological diseases with mitochondrial impairment. His latest work was published in Cell Stem Cell in January 2017 and demonstrated the use of iPSC-derived neural cells for drug discovery of neurological disorders caused by mitochondrial DNA mutations.

    Abstract:

    Mitochondrial defects represent a common pathogenetic mechanism associated with neurodegeneration. At the same time, mitochondrial DNA (mtDNA) mutations frequently cause neurological diseases. Addressing the mechanisms underlying mitochondrial impairment in patient-derived neural cells may therefore lead to the identification of therapeutic strategies counteracting neurodegeneration.

    A critical element for cell-based drug discovery is the use of cells that are homogeneous and obtainable in a reproducible manner. We recently showed that NPCs derived from human induced pluripotent stem cells (iPSCs) represent an effective model system for mtDNA disease drug discovery (Lorenz et al, Cell Stem Cell 2017). Here, we present how we derive NPCs and post-mitotic neurons in a robust manner in order to use these cells for therapeutic screenings. Finally, we describe how to analyze the mitochondrial and metabolic properties of the patient-derived cells and how to set up high-content analysis (HCA)-based compound screening strategies.

     


    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    MAY 24, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    Loading Comments...